Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents

In this satellite symposium, experts discuss the optimal management strategy for patients with CLL, including evidence-based best practices and practical application of the NCCN Guidelines. Download the slides from this dynamic satellite symposium and a clinician resource to learn more about current treatment algorithm and ongoing clinical trials in CLL.
Asher Chanan-Khan, MD
Thomas J. Kipps, MD, PhD
Anthony Mato, MD
William G. Wierda, MD, PhD

Downloadable Slidesets

Download these slides from our ASH 2019 live satellite symposium on CLL to review the current state of CLL diagnosis and evaluation as well as targeted agents being used to treat CLL.

Thomas J. Kipps, MD, PhD Released: December 5, 2019

Download these slides from our ASH 2019 live satellite symposium on CLL to review the most current clinical data on treating patients with newly diagnosed CLL.

Anthony Mato, MD Released: December 5, 2019

Download these slides from our ASH 2019 live satellite symposium on CLL to review the most current clinical data on treating patients with relapsed/refractory CLL.

Asher Chanan-Khan, MD Released: December 5, 2019

Download these slides from our ASH 2019 live satellite symposium on CLL to review promising agents and combination therapies currently under investigation in CLL.

William G. Wierda, MD, PhD Released: December 5, 2019
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Pharmacyclics, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue